A $3.2M NIH grant will support groundbreaking AI-driven research by WashU’s Ganesh Chand, PhD, to uncover mechanisms behind neuropsychiatric symptoms in Alzheimer’s.
NEURO360 partner, C2N Diagnostics, is set to occupy just over half of the new space in WashU’s $100 million redevelopment, leaving room for other growing bioscience companies. Read the entire announcement on St. Louis Magazine’s website by clicking here.
NEURO360 partner, Avadel Pharmaceuticals, is expanding its sleep medicine pipeline with a new potential therapy, valiloxybate for treatment of narcolepsy and idiopathic hypersomnia. Read the press release at Avadel Pharmaceuticals’ website by clicking here.
NEURO360, BioSTL’s NSF Engines grant application with WashU, faced delays due to federal funding shifts—but we’re back on track. Our commitment to making St. Louis a leader in neuroscience innovation remains strong, regardless of the NSF outcome.
A new AI-based technology that rapidly maps the brain to locate sensitive areas that control speech, vision, movement and other critical functions has received authorization from the Food and Drug Administration (FDA), enabling it to be marketed to hospitals with the aim of enhancing the precision of neurosurgeries. The technology was developed by researchers and […]
Researchers at Washington University School of Medicine in St. Louis have received an $11.85 million grant to create a resource for the WashU and national research communities to study the growing number of neurodevelopmental and psychiatric disorders known to be caused by a single gene mutation. Read the entire article on the Washington University Newsroom […]
In a recent study, researchers at WashU Medicine found adverse events were rare and manageable among clinic patients with very mild or mild Alzheimer’s disease who received lecanemab infusions at the Memory Diagnostic Center at WashU Medicine. Read the entire article on the Washington University Newsroom website by clicking here.
When a person sustains an injury to the spinal cord, the normal communication between the brain and the spinal circuits below the injury are interrupted, resulting in paralysis. Because the brain is functioning normally, as is the spinal cord below the injury, researchers have been working to re-establish the communication to allow for rehabilitation and […]
Neuro360 Donn Reuben on BioStL and NEURO360 360 Degrees of Neurological Innovation Read More Chemotherapy can be lifesaving, but can also leave patients with debilitating side effects. These include cognitive impairments in processing speed, memory, executive function, and attention. Saint Louis University pain researcher Daniela Salvemini joins us to discuss “chemo brain.” Lingering symptoms can […]
St. Louis-based Washington University School of Medicine’s $616M neuroscience center, which began construction in spring 2020, has reached its structural completion, St. Louis Business Journal reported Aug. 11. The 11-story, 609,000-square-foot neuroscience research building will house more than 100 research teams with 875 researchers focusing on Alzheimer’s disease, brain tumors, spinal cord injury and psychiatric […]
